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0.14) was observed, and there were no differences detected 
between sexes. VAT was strongly associated with leptin with 
a greater effect in women than in men. Leptin was strongly 
associated with TSH.  Conclusions: No association between 
TSH and VAT was observed. Other biomarkers such as leptin 
may play a role in the relationship between thyroid function 
and metabolic risk.  © 2016 European Thyroid Association
Published by S. Karger AG, Basel 
 Introduction 
 Both thyroid disease and obesity are common disor-
ders in the general population. Several studies have found 
a prevalence dependent on selected reference ranges from 
0.1 to 2% for hypothyroidism [elevated thyroid-stimulat-
ing hormone (TSH), low thyroid hormones] and >1% for 
hyperthyroidism (decreased TSH, elevated thyroid hor-
mones)  [1, 2] . The prevalence for subclinical hypothy-
roidism (elevated TSH only) can range between 4 and 
10%  [1, 2] . Recent global reports estimate that 36.9% of 
men and 38.0% of women are classified as having obesity 
based on body mass index (BMI), and trends have shown 
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 Abstract 
 Background: Abdominal obesity is a major driver for ad-
verse medical conditions. While an interaction between adi-
pose tissue and thyroid function is thought to exist, to our 
knowledge, no study has examined the effect of thyroid-
stimulating hormone (TSH) on visceral adipose tissue (VAT) 
in a population-based context.  Objective: We determined 
an association between serum TSH levels and VAT.  Methods: 
A sample of 1,021 female and 956 male adults aged 20–79 
years was drawn from registry offices in the cross-sectional, 
population-based Study of Health in Pomerania Trend (SHIP 
Trend) in Northeast Germany from 2008 to 2012. Our main 
exposure was serum TSH levels. Our main outcome was VAT 
measured using magnetic resonance imaging. The possibly 
mediating role of leptin on the TSH-VAT association was also 
assessed.  Results: A total of 1,719 participants (87.9%) had 
serum TSH levels within the reference range. The mean vol-
ume of VAT was 5.33 liters for men and 2.83 liters for women. 
No association between TSH and VAT (β = 0.06, 95% CI: –0.02, 
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a considerable increase in the past few decades  [3] . Simi-
lar increases in the proportion of obese people have been 
observed in Northeast Germany  [4] . The Western Pomer-
ania geographical region has experienced an increase 
from 24.7 to 32.0% in the proportions of individuals who 
were obese  [4] , making this region one of the highest 
prevalent regions in Germany (from 20.7% in 2008 to 
23.6% in 2011 on average)  [5] .
 Several mechanisms have been proposed to describe 
the interaction between thyroid hormones and adipose 
tissue. Thyroid hormone induces energy utilization in 
white adipocytes through induction of uncoupling pro-
tein 1 expression  [6] . In obesity, the expression of both 
the TSH receptor and thyroid hormone receptor gene was 
shown to be reduced in both subcutaneous (SAT) and 
visceral (VAT) adipose tissues  [7] . Conversely, preadipo-
cytes and other adipocytokines of those adipose tissues 
produce fT 3 and may impact hypothalamic-pituitary-
thyroid axis activity  [8] .
 Leptin is discussed as a potential mediator in the rela-
tionship between TSH and VAT  [9] . It regulates the se-
cretion of thyrotropin-releasing hormone and TSH di-
rectly on the level of the paraventricular nucleus and in-
directly on the level of the arcuate nucleus  [10, 11] . Both 
the hypothalamic-thyroid axis and leptin loop system are 
known to modify certain signaling processes in the hypo-
thalamic nuclei, but the association between them is still 
unclear  [12, 13] .
 The assessment of the interplay between thyroid hor-
mones and adipose tissue is further complicated by the 
inability to easily measure adiposity. Most studies use 
BMI as a surrogate measure for fat mass, and recent cross-
sectional studies demonstrated highly variable results 
with trends to significant associations between TSH and 
BMI  [14–17] . Longitudinal studies have demonstrated 
predominantly a positive association between the change 
of serum TSH levels and the change of BMI or body 
weight  [18–20] . However, others have demonstrated con-
flicting data proposing that lean body mass may impact 
thyroid function  [21] . To account for differences in body 
mass and specifically body fat distribution, the actual 
VAT and SAT should ideally be measured with imaging 
technologies. In the 4 studies we found, inconsistent re-
sults were observed  [22–25] .
 We (1) ascertained the association between serum 
TSH levels and VAT measured using whole magnetic res-
onance imaging (MRI), (2) determined whether thyroid 
function was associated with anthropometric measures, 
and (3) evaluated whether leptin influenced this relation-
ship.
 Subjects and Methods 
 Study Population 
 The Study of Health in Pomerania Trend (SHIP-Trend) is
an ongoing population-based cohort study carried out in West 
Pomerania, a region in Northeast Germany. The baseline survey 
was conducted from 2008 to 2012. A sample of adults aged 20–79 
years was drawn from population registries out of the total popu-
lation of 212,157 inhabitants, of which 8,016 inhabitants were 
invited to participate from 2008 to 2012. The final cohort con-
sisted of 4,220 subjects, all of whom gave their written informed 
consent (response 50.1%). We excluded 2,449 participants be-
cause of missing MRI data and analyzed data from 1,971 partici-
pants. The institutional review boards at all respective institu-
tions approved the conduct and secondary data analysis for this 
study.
 Assessments 
 Trained and certified interviewers conducted a computer-aid-
ed personal interview to collect information on medical history, 
behavioral, and sociodemographic characteristics. Subjects were 
categorized into current, former, and never-smokers according to 
self-report. Self-reported average alcohol consumption relative to 
the last 30 days was calculated according to Baumeister et al.  [26] . 
We defined physical activity as a self-report of sporting activities 
lasting at least 2 h a week. To calculate the equivalent income of a 
household, we divided the mean income by the square root of the 
number of people living in a household  [27] .
 Blood samples were drawn between 7 a.m. and 1 p.m. from the 
antecubital vein and analyzed immediately in the hospital labora-
tory. Participants without known diabetes fasted at least 8 h before 
the examination. The median fasting time before blood sampling 
was 10.7 h. We determined serum TSH levels through immuno-
chemiluminescent procedures (Dimension Vista; Siemens Health-
care Diagnostics, Eschborn, Germany). The analytical sensitivity 
of the TSH assay was 0.005 mIU/l, and the TSH working range was 
0.005–100 mIU/l. The interassay coefficients of variations (CV) 
were 2.04% (low) or 2.20% (high) for TSH. We defined the TSH 
reference range as 0.49–3.29 mIU/l  [28] . Levels of LDL cholesterol 
[CV: 3.9% (low) and 4.3% (high)] and HDL cholesterol [CV: 4.7% 
(low) and 5.1% (high)] were determined using the liquid selective 
detergent method (Dimension Vista), and cholesterol and triglyc-
eride levels were assessed using photometric methods (Dimension 
Vista; Flex reagent cartridge; Dade Behring Ltd., Milton Keynes, 
UK). The CVs were 3.18 and 3.74% (cholesterol) and 3.4 and 4% 
(triglycerides).
 A standardized protocol for the MRI examination was em-
ployed  [29] . Participants without medication allergies had the op-
tion to undergo a contrast-enhanced examination. All examina-
tions were performed on a 1.5-tesla machine (Magnetom Avanto; 
Siemens Medical Systems, Erlangen, Germany). Participants were 
placed in the supine position, and 5 phased array surface coils were 
placed on the head, neck, abdomen, pelvis, and lower extremities. 
The spinal coil was embedded in the patient table. The basic pro-
gram included native whole-body MRI and secretin-enhanced MR 
cholangiopancreatography. Two trained technicians performed all 
examinations in a standardized manner. Data analysis was per-
formed with ‘ATLAS’ (Automatic Tissue Labelling Analysis Soft-
ware), which was specifically programmed for this purpose  [30] . 
Two readers were trained for 2 weeks and independently deter-
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mined visceral and subcutaneous body fat (intraclass correlation 
coefficient >0.997).
 Body height was measured to the nearest 0.1 cm using a por-
table stadiometer (Soehnle Personenmessgerät; Soehnle Industrial 
Solutions, Backnang, Germany) and weight was measured to the 
nearest 0.1 kg with electronic scales (Soehnle S20, Soehnle Indus-
trial Solutions, Backnang, Germany). BMI was calculated by taking 
the ratio of weight (in kg) to height (m) squared. Waist circumfer-
ence was measured at the narrowest point between the last rib and 
the highest point of iliac crest to the nearest 0.1 cm. Hip circumfer-
ence was measured at the midpoint of the iliac crest and the most 
lateral projecting points of the greater trochanter to the nearest 0.1 
cm. The waist-to-hip ratio was calculated by taking the ratio of 
waist circumference to hip circumference, and the waist-to-height 
ratio was calculated as the ratio of waist circumference to height 
(cm).
 Statistical Methods 
 Quantitative characteristics are expressed as means ± SD, and 
qualitative characteristics are expressed as total numbers and per-
centages. We tested for an effect modification by including inter-
action terms of TSH with sex and smoking status in the regression 
models  [14] . We assessed TSH as a continuous variable, and sub-
categorized TSH as high, low, and normal, based on the reference 
range. The primary exposure of our analysis was serum TSH. The 
primary outcome was VAT. To account for nonparticipation in 
the voluntary MRI examination, we used inverse probability 
weights derived from logistic regression with participation in the 
MRI examination (yes/no) as outcome and adjusted for age, sex, 
level of education, income, marital status, smoking status, physi-
cal activity, BMI, diabetes, cholesterol, triglycerides, TSH, systol-
ic, and diastolic blood pressure, hypertension medication, and 
hemoglobin A 1C as exposures. For all subsequent regression anal-
yses, we used fractional polynomials to test for potential nonlin-
ear associations. Unadjusted regression models (β-coefficient, 
95% CI) were assessed. β-Coefficients were utilized to ensure the 
variances of dependent and independent variables were a value
of 1 [i.e. an increase of 1 mU/l TSH equals an increase of x 
(β-coefficient) liter fat)], when the main exposure and outcome 
variable were considered. Our multivariable model was adjusted 
for age, sex, smoking status, physical activity, and alcohol intake. 
We performed an exploratory analysis by performing a regression 
model of VAT and leptin, and leptin and TSH, adjusting for the 
same confounders as above. As serum leptin levels were available 
in a subsample of 851 participants, we created an inverse proba-
bility weight in a similar fashion, and multiplied for the leptin 
analyses the weight with the previous MRI weight. To minimize 
the effect of outliers on the results, we power-transformed the 
leptin variable using the Royston-Sauer power transformation 
method  [31] . Lastly, we determined adjusted β-coefficients for 
differing anthropometric measurements and thyroid function. 
The outcomes of interest included BMI, waist and hip circumfer-
ence, waist-hip ratio, and SAT. Separate models were constructed 
to assess each of these outcomes. p < 0.05 was initially considered 
statistically significant. We used the Bonferroni correction meth-
od to adjust for multiple comparisons  [32] . The 21 comparisons 
in the main analysis yielded a new threshold of p < 0.002. Analy-
ses were performed using Stata 14.0 (StataCorp, College Station, 
Tex., USA).
 Results 
 A total of 87.9% of all participants had serum TSH lev-
els within the reference range, while 9.2% had decreased 
TSH levels and 2.9% had increased TSH levels. The serum 
TSH levels in men were significantly lower than in wom-
en ( table 1 ). The volume of VAT in men was twice as high 
as in women, whereas women had a significantly higher 
volume of SAT. Women tended to have higher choles-
terol levels and HDL cholesterol levels, whereas men had 
higher triglyceride levels. In both sexes, BMI, waist cir-
cumference, and waist-to-height ratio were all signifi-
cantly higher in men than in women.
 Table 1.  Characteristics of the study population
Male Female p value
Subjects, n 956 1,021
Age, years 50.8 ± 14.5 50.9 ± 13.4 0.78
Sociodemographic factors
Smoking status <0.001
Current smoker 239 (25.1) 231 (22.6)
Former smoker 411 (43.1) 314 (30.8)
Nonsmoker 303 (31.8) 475 (46.6)
Exercise, >2 h/week 672 (70.5) 734 (71.3) <0.001
Alcohol, g/day in last 7 days 12.7 ± 15.2 4.1 ± 5.9 <0.001
Equivalent income, EUR 1,548 ± 792 1,382 ± 673 <0.001
Married 789 (82.8) 803 (78.7) <0.001
Comorbidities
Myocardial infarction 12 (1.3) 3 (0.3) <0.001
Any diabetes 82 (8.6) 81 (7.9) 0.59
Lipid profile
Total cholesterol, mmol/l 5.41 ± 1.08 5.61 ± 1.06 <0.001
LDL cholesterol, mmol/l 3.43 ± 0.92 3.40 ± 0.92 0.52
HDL cholesterol, mmol/l 1.30 ± 0.32 1.61 ± 0.36 <0.001
Triglycerides, mmol/l 1.75 ± 1.25 1.36 ± 0.74 <0.001
Leptin, ng/ml 6.91 ± 4.85 21.36 ± 14.27 <0.001
Thyroid function
TSH, mIU/l 1.26 ± 0.75 1.42 ± 1.08 <0.001
Body composition measures
Visceral fat, liters 5.33 ± 2.82 2.83 ± 1.88 <0.001
Subcutaneous fat, liters 6.88 ± 2.89 8.96 ± 3.76 <0.001
BMI 28.0 ± 3.6 27.1 ± 4.9 <0.001
Waist circumference, cm 95.3 ± 10.8 83.7 ± 11.9 0.38
Hip circumference, cm 101 ± 7.0 102 ± 10.5 <0.001
Waist-to-hip ratio 0.94 ± 0.07 0.82 ± 0.06 <0.001
Waist-to-height ratio 0.54 ± 0.02 0.51 ± 0.02 <0.001
 Data are expressed as means ± SD for continuous data or as
n (%) for categorical data.
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 We found that the association between TSH and VAT 
was not effect-modified by sex, but by smoking (p < 0.001 
for effect modification through smoking). There was no 
association observed between TSH and VAT, and there 
were no associations between low or high TSH and VAT. 
We reported β-coefficients because we only found linear 
associations between TSH and VAT ( table 2 ). In the un-
adjusted analysis between TSH and VAT, we observed a 
significant inverse relationship (p < 0.001), which became 
nonsignificant after adjusting for covariates. Second, we 
observed a significant inverse association of a normal 
TSH with VAT (p = 0.004) in the adjusted multivariable 
analysis, but neither low nor high TSH were significantly 
associated with VAT. 
 We compared our primary outcome of VAT with oth-
er anthropometric measures of adiposity in fully adjusted 
regression models ( table 3 ) and demonstrated an initially 
significant association between TSH and waist-to-height 
ratio (p = 0.046). No association was observed between 
TSH and SAT, BMI, waist circumference, hip circumfer-
ence, or waist-to-height ratio. We explored the role of 
leptin in 2 multivariable analyses in 366 men and 485 
women. The association of leptin and VAT was exponen-
tial and stronger for women than for men (both p < 0.001, 
 fig. 1 ). The analysis of the association between TSH and 
leptin yielded also a weaker but highly significant (p < 
0.001) relationship ( fig. 2 ).
 A subgroup analysis by smoking status raised the pos-
sibility of a positive association (p = 0.005) among former 
smokers ( table 4 ). As a further exploratory analysis, we 
divided the normally distributed age into quartiles, and 
stratified by sex and BMI (data not shown), but did not 
detect any association between TSH and VAT. Applying 
the Bonferroni correction on the results made the asso-
ciations of TSH and waist-to-height ratio as well as the 
result for former smokers insignificant.
 Discussion 
 We found no association between serum TSH and the 
volume of VAT. However, leptin could be a possible link 
as it is associated with both VAT and TSH.
 As the first population-based study using MRI tech-
niques to ascertain body fat and its relation with thyroid 
function, the present study’s results align well with find-
ings of a Greek prevention study of healthy individuals 
that failed to show an association between TSH levels and 
visceral fat thickness  [22] . Likewise, a Belgian study dem-
onstrated that there were no associations between TSH 
and the whole body fat mass, and a South Korean study 
in men found no association between TSH and visceral 
and subcutaneous fat area  [23, 25] . Our study differed in 
that the volume of VAT in the aforementioned studies 
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 Fig. 1. Association between VAT and leptin. VAT was measured 
by interpretation of whole body MRIs, and serum leptin levels were 
determined in blood samples. 
 Fig. 2. Association between leptin and TSH. Serum leptin levels 
and TSH were determined in blood samples. 
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was measured using computer tomography or indirectly 
via the measurement of preperitoneal fat with ultrasound. 
An Italian study in patients with obesity used computer 
tomography scans to determine VAT and showed a sig-
nificant association of TSH and VAT  [24] . Their sample 
size was fairly small and the characteristics of an obese 
population certainly differ from our general population 
sample  [33] .
 Comparable population-based studies have not spe-
cifically assessed VAT or SAT, but used anthropometric 
markers. Focusing our secondary analysis on these rela-
tionships, we did not observe similar results. We were 
unable to replicate the association between TSH and BMI 
in women from a previous, independent SHIP examina-
tion performed in the same study region  [14] , despite ad-
justing for the same confounders and stratifying by sex. 
 Table 2.  Association between TSH and VAT for the overall population
Subjects,
n
Crude  Adjusted
β-coefficient 95% CI β-coe fficient 95% CI
TSH 1,955 –0.30 –0.43, –0.17 0.06 –0.02, 0.14
Low TSH 179 –0.52 –3.94, 2.92 –1.72 –4.86, 1.42
High TSH 57 –0.12 –0.35, 0.11 0.10 –0.04, 0.24
TSH within reference range 1,719 –0.42 –0.66, –0.19 –0.41 –0.69, –0.13
 Low TSH = <0.49 mIU/l; high TSH = >3.29 mIU/l; TSH within reference range = 0.49 – 3.29 mIU/l. Adjusted 
model includes age, sex, smoking, physical activity, and alcohol intake as covariates.
 Table 3.  Association between TSH and anthropometric markers
β-coefficient 95% CI Standardized 
β-coefficient
VAT (MRI) (liters) 0.06 –0.02, 0.14 1.44
SAT (MRI) (liters) 0.10 –0.06, 0.26 1.22
BMI 0.16 –0.05, 0.36 1.49
Waist circumference (cm) 0.43 –0.03, 0.90 1.84
Hip circumference (cm) 0.16 –0.22, 0.54 0.84
Waist-to-hip ratio 0.01 0.00005, 0.005 2.00
Waist-to-height ratio 0.01 –0.0007, 0.006 1.50
 Adjusted model includes age, sex, smoking, physical activity, and alcohol intake as covariates. Standardized 
β-coefficient = β-coefficient/standard error.
 Table 4.  Association between TSH and VAT stratified by smoking status
Subjects,
n
Crude  Adjusted
β-coefficient 95% CI β-co efficient 95% CI
Never smokers 771 –0.30 –0.51, –0.08 –0.02 –0.12, 0.08
Former smokers 716 –0.23 –0.43, –0.03 0.18 0.06, 0.31
Current smokers 468 –0.40 –0.63, –0.17 –0.01 –0.23, 0.22
 Adjusted model includes age, sex, smoking, physical activity, and BMI as covariates.
 Association between TSH and Visceral 
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The association was weak and, compared to this study, 
there was a different baseline response which could have 
resulted in a different selection bias. More importantly, in 
the 10 years between the previous SHIP examination and 
our study, many characteristics had changed, for exam-
ple, an increased iodine supply  [4] . Results of other pop-
ulation-based studies have been mixed. Recent longitudi-
nal data suggested an association between the change of 
TSH and the change of body fat; however, no association 
has been observed in baseline TSH and change in body fat 
or in change in TSH and baseline body fat measurements 
 [19, 20] . Despite the prospective design of these studies, 
a causal link could not be proven beyond doubt  [20] . A 
large Norwegian study found a positive association be-
tween TSH and BMI in a cross-sectional approach,  [34] , 
whereas an Australian and Dutch study did not  [15, 16] . 
The Norwegian sample was large (n = 27,097); however, 
only subjects older than 40 years were included in the 
study, which could have affected the representativeness 
of the study  [34] . It has been shown that anthropometric 
measures change with age  [35] , which is also true for se-
rum TSH levels  [36] . More importantly, these studies re-
lied solely on anthropometric surrogates for the relation-
ship of TSH and fat, yet BMI can be a fairly inaccurate 
measure for adiposity, particularly in men and in the el-
derly  [37] .
 Our results may indicate that the volume of VAT may 
not necessarily correspond to the density of TSH recep-
tors and thyroid hormone receptor α 1 , which are ex-
pressed on preadipocytes and adipocytes and which are 
important regulators of adipocyte differentiation  [38] . 
The exact role of the receptors of TSH receptors and thy-
roid hormone receptor α 1 within the described relation-
ship between thyroid function and VAT remains incom-
pletely understood. One study of 119 subjects found a sig-
nificantly reduced number of TSH receptors in adipose 
tissue in people with obesity  [39] , while another showed 
an increased TSH receptor expression in obese mice and 
humans  [38] . Although purely speculative, TSH recep-
tors may be distributed unevenly throughout the VAT, 
suggesting that the effects of fT 3 or fT 4 on total weight loss 
do not correlate with the hormone dose  [40] . Other pos-
sibilities to explain the lack of a direct association between 
TSH and VAT include impaired water homeostasis in 
persons with low thyroid function  [41] or the existence of 
a latency period between the onset of TSH decrease and 
the increase of the visceral fat volume  [18] . According to 
these speculations, a certain proportion of participants 
with low TSH levels may only develop an increase in vis-
ceral fat in the future.
 Although we did not prove a direct association between 
VAT and TSH, we propose that leptin may be a possible 
link in this pathway as it is strongly associated with both 
VAT and TSH in the VAT-leptin-TSH pathway  [25] . VAT 
produces a number of adipokines, including leptin  [42] , 
which may influence and regulate the secretory capacity 
of the thyroid gland as well as the production of thyrotro-
pin-releasing hormone in the pituitary gland  [10, 11] . 
While the VAT-leptin association has been well studied 
and the association of SAT with leptin is even stronger 
 [43] , we concur that further studies are needed not only to 
prove the leptin-TSH association, but also to show that 
leptin is secreted from nonadipose tissues  [44–46] . Two 
possibilities may explain our findings of no direct but in-
direct association of VAT and TSH via leptin if we con-
sider a causal pathway between VAT and TSH: (1) the per-
centage of VAT compared to other adipose tissue is high-
ly variable in a population which would confound the 
relationship, and (2) the adipokine production within ad-
ipose tissue is disproportional and uneven  [47] . Indicative 
for this hypothesis is that studies have shown that there is 
at least regional variation in the expression of the leptin 
gene expression  [48] . We considered the inverse associa-
tion between TSH within the reference range and VAT as 
a chance finding, given that there are no physiological ex-
planatory models that could support this association and 
the nonsignificance after accounting for multiple analyses.
 To our knowledge, this study is the first to examine the 
association of TSH and VAT in a large study sample. Un-
like previous studies, we included both women and men in 
our study and chose a population-based approach with a 
geographically circumscribed sample, a strength in this ep-
idemiology study that allows extrapolation to other regions 
with similar demographic characteristics  [23–25] . Such a 
study design minimizes the referral and selection bias ob-
served in studies conducted in tertiary care centers  [49] . 
MRI ascertainment of body fat avoided the need to utilize 
anthropometric measures which are known to be suscep-
tible to measurement bias  [50] . Our relatively high partici-
pant number allowed us to assess subtle associations.
 We recognize that this study has a number of limita-
tions. The cross-sectional design does not allow us to de-
termine causality and we caution the reader that our re-
sults imply associations only. Longitudinal data will be 
available with the follow-up study of SHIP-Trend after 
2017 and could certainly confirm our results, although it 
is possible that our sample size is still too small for a po-
tential weak association. A considerable nonresponse rate 
(49%) was observed which may risk biasing the analyses. 
This number has to be accounted for within the context 
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of declining participation in large-scale population-based 
studies affecting other major cohort studies  [51] . Further 
methodological research should examine the extent of the 
representativeness of this research. It remains possible 
that a positive association may have been overlooked in 
specific subgroups due to insufficient statistical power. 
We also acknowledge the lack of data on other thyroid 
hormones including fT 3 , fT 4 , thyroid peroxidase, and 
thyroid receptor antibodies, including plasma levels of 
free fatty acids and interleukin 6. However, we believe 
that TSH as the most sensitive marker of thyroid function 
is the appropriate parameter to measure this association. 
There is some inconsistency in the anatomical bound-
aries of the abdomen, which could alter the measurement 
of VAT  [52] , but they are naturally still more accurate 
than the anthropometric measures which can only serve 
as crude indicators of adiposity. Finally, we applied a very 
conservative approach to test significance using the Bon-
ferroni correction and recognize that this compromised 
the significance of our results.
 To conclude, we could not demonstrate a direct asso-
ciation between TSH and VAT in the surveyed population 
in West Pomerania. Longitudinal population-based stud-
ies with larger sample sizes and research in other regions 
have to be conducted to confirm the results of this study.
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